DCAT Week 2025 Recap: Abzena’s CSO sits down with Chats with Chaudhrey

In a recent episode of Chats with Chaudhrey, our CSO, Dr Campbell Bunce sat down with life science blogger Rizwan Chaudhrey to recap all the key topics and trends that were discussed at this year’s DCAT Week event in NYC on March 17-20.  In the interview, Campbell shares his thoughts on the key things that customers were talking about during the week from AI and speed to market to emerging modalities and supply chain resiliency.

Regarding emerging modalities Campbell shares, “Now we’re seeing the drug conjugates continue to gather momentum and we see more and more of ADCs coming into the clinic and being approved. I think the sector understands, antibodies and I don’t think they’re going to go away anytime soon. But in the biologics front what we’re seeing more and more are bispecifics, specifically T cell engagers. We’ve seen a lot of news around T-cell engagers as the potential next-gen Car-T kind of therapeutics, and I’m not surprised. We’ve learned a lot about how to efficiently design and make antibody like structures that have dual functionality.  It’s really exciting for the team to be working on those kinds of things and designing them. While you get a standard bispecific using knob into hole technology, we’re seeing sort of fusion protein type designs where one arm’s maybe a VH, and then there’s another.  But also new cargoes, so new functional modalities like Oligo conjugates or antibody Oligo conjugates. We’re seeing a lot more of those, and it’s quite a new modality that needs design elements around it. For stability it needs analytics, method development for characterization, relation, stability testing activity as well, bioassays. We’re really fortunate to see a lot of these new modalities coming through and excited to be part of that as well in helping get a few of these into the clinic.”

Watch the full interview here: